RPL17 and head and neck squamous cell carcinoma: This regimen remained the standard of care for the subsequent decade until the KEYNOTE - 048 and CHECKMATE - 141 studies in 2018 demonstrated the efficacy of PD - 1 immune checkpoint inhibitors in r/m HNSCC (11).